Literature DB >> 20721957

Differential proteomic profiling of chordomas and analysis of prognostic factors.

Hua Zhou1, Chang-bao Chen, Jie Lan, Chao Liu, Xiao-guang Liu, Liang Jiang, Feng Wei, Qing-jun Ma, Geng-ting Dang, Zhong-jun Liu.   

Abstract

BACKGROUND: The recurrence rate of chordoma is high, and the prognosis is poor.
METHODS: Differential proteomic analysis was performed on chordomas and adjacent normal tissues, with verification by Western blot. Protein expression was evaluated by immunohistochemistry of 37 chordomas. Association of candidate protein expression with clinical parameters, disease-free survival, and overall survival were analyzed.
RESULTS: We identified 14 up-regulated and 5 down-regulated proteins in chordomas. Expression of alpha enolase (ENO1), pyruvate kinase M2 (PKM2), and gp96 was higher in recurrences than in primary tumors. Univariate analysis showed that significantly adverse factors for disease-free survival were overexpression of ENO1 and PKM2, involvement of contiguous vertebral levels, and inadequate surgical margin at initial surgery. Inadequate surgical margin without radiotherapy, involvement of contiguous vertebral levels, and cervical spine location were adverse factors for overall survival. By multivariate analysis, independent adverse prognostic factors were inadequate surgical margin and involvement of multiple contiguous vertebral levels for recurrence; upper cervical spine location and involvement of contiguous vertebral levels for tumor-related death. Multivariate analysis failed to show the significance of the proteins.
CONCLUSIONS: Involvements of multiple contiguous vertebral levels and upper cervical spine, rather than overexpression of ENO1, PKM2, or gp96, are independent prognostic indicators for chordomas. 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20721957     DOI: 10.1002/jso.21674

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  11 in total

1.  Establishment and characterization of a primary human chordoma xenograft model.

Authors:  I-Mei Siu; Vafi Salmasi; Brent A Orr; Qi Zhao; Zev A Binder; Christine Tran; Masaru Ishii; Gregory J Riggins; Christine L Hann; Gary L Gallia
Journal:  J Neurosurg       Date:  2012-01-27       Impact factor: 5.115

Review 2.  Chordoma in children: Case-report and review of literature.

Authors:  Jean-Louis Habrand; Jean Datchary; Stéphanie Bolle; Anne Beaudré; Ludovic de Marzi; Kévin Beccaria; Dinu Stefan; Jacques Grill; Rémi Dendale
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-08

3.  Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines.

Authors:  Isaac O Karikari; Christopher L Gilchrist; Liufang Jing; David A Alcorta; Jun Chen; William J Richardson; Mostafa A Gabr; Richard D Bell; Michael J Kelley; Carlos A Bagley; Lori A Setton
Journal:  J Neurosurg Spine       Date:  2014-06-06

Review 4.  The molecular aspects of chordoma.

Authors:  Sukru Gulluoglu; Ozlem Turksoy; Aysegul Kuskucu; Ugur Ture; Omer Faruk Bayrak
Journal:  Neurosurg Rev       Date:  2015-09-12       Impact factor: 3.042

Review 5.  Reprint of "Chordoma in children: Case-report and review of literature".

Authors:  Jean-Louis Habrand; Jean Datchary; Stéphanie Bolle; Anne Beaudré; Ludovic de Marzi; Kévin Beccaria; Dinu Stefan; Jacques Grill; Rémi Dendale
Journal:  Rep Pract Oncol Radiother       Date:  2016-04-18

6.  Prognostic value of MIB-1, p53, epidermal growth factor receptor, and INI1 in childhood chordomas.

Authors:  Rajni Yadav; Mehar Chand Sharma; Prit Benny Malgulwar; Pankaj Pathak; Elanthenral Sigamani; Vaishali Suri; Chitra Sarkar; Amandeep Kumar; Manmohan Singh; Bhawani Shankar Sharma; Ajay Garg; Sameer Bakhshi; Mohammed Faruq
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

7.  Integrated miRNA-mRNA analysis revealing the potential roles of miRNAs in chordomas.

Authors:  Cheng Long; Liang Jiang; Feng Wei; Chuan Ma; Hua Zhou; Shaomin Yang; Xiaoguang Liu; Zhongjun Liu
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

8.  Experimental study on differences in clivus chordoma bone invasion: an iTRAQ-based quantitative proteomic analysis.

Authors:  Zhen Wu; Liang Wang; Zhengguang Guo; Ke Wang; Yang Zhang; Kaibing Tian; Junting Zhang; Wei Sun; Chunjiang Yu
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

9.  Three are better than one: plasminogen receptors as cancer theranostic targets.

Authors:  Patrizia Ceruti; Moitza Principe; Michela Capello; Paola Cappello; Francesco Novelli
Journal:  Exp Hematol Oncol       Date:  2013-04-17

Review 10.  Pyruvate kinase M2 fuels multiple aspects of cancer cells: from cellular metabolism, transcriptional regulation to extracellular signaling.

Authors:  Ming-Chuan Hsu; Wen-Chun Hung
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.